Basic Information
Lamictal Tablet 25 mg
TABLET
Regulatory Information
SIN14088P
February 3, 2012
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN03AX09
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 25.0 mg
Detailed Information
Contraindications
**Contraindications** _LAMICTAL_ tablets and dispersible/chewable tablets are contraindicated in individuals with known hypersensitivity to lamotrigine or any other ingredient of the preparation.
Indication Information
**Indications** **EPILEPSY** - **Adults and Adolescents (over 12 years of age)** _LAMICTAL_ is indicated for use as adjunctive or monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome. - **Children (2 to 12 years of age)** _LAMICTAL_ is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with Lennox-Gastaut syndrome. Initial monotherapy treatment in newly diagnosed paediatric patients is not recommended. After epileptic control has been achieved during adjunctive therapy, concomitant anti-epileptic drugs (AEDs) may be withdrawn and patients continued on _LAMICTAL_ monotherapy. _LAMICTAL_ 2 mg dispersible/chewable tablet is not available locally. If the calculated dose in children is less than 2.5 mg daily, then _LAMICTAL_ cannot be used. DO NOT attempt to administer partial quantities of the dispersible/chewable tablets. **BIPOLAR DISORDER** - **Adults (18 years of age and over)** _LAMICTAL_ is indicated for the prevention of depressive episodes in patients with bipolar disorder. Safety and efficacy of _LAMICTAL_ in the acute treatment of mood episodes has not been established. The physician who elects to use _LAMICTAL_ for periods extending beyond 18 months should periodically re-evaluate the long-term usefulness of the drug for the individual patient.